## COVID-19 Vaccine
(6 months through 17 years of age)

### Vaccine Description

(See Manufacturer EUA Fact Sheets for specific vaccine components)

- mRNA vaccines
  - Pfizer-BioNTech COVID-19 Vaccine (2023-24 Formula) EUA Fact Sheet – 6 Months through 11 Years
  - Moderna COVID-19 Vaccine (2023-24 Formula) EUA Fact Sheet – 6 Months through 11 Years
  - Pfizer-BioNTech (Comirnaty) 2023-24 Formula Package Insert
  - Moderna (Spikevax) 2023-24 Formula Package Insert

- Protein subunit vaccine [12 years and older]
  - Novavax 2023-24 Formula Package Insert

### Route (all)

- Intramuscular (IM)

### Indications

- COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19.

### Dosing & Administration

- **Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)**
- **Pfizer-BioNTech (Comirnaty) 2023-24 Formula CDC Guidance**
- **Moderna COVID-19 Vaccine (2023-2024 Formula)**
- **Moderna (Spikevax) 2023-24 Formula CDC Guidance**
- **Novavax 2023-24 Formula CDC Guidance**

*The recommended vaccine type and number of updated (2023-2024 Formula) COVID-19 vaccine doses are based on age on the day of vaccine administration, vaccination history, and immune status.

- COVID-19 vaccination schedules for ages 6 months and older who are NOT immunocompromised.
- COVID-19 vaccination schedules for ages 6 months and older who ARE immunocompromised.
  - For children who transition from age 4 years to 5 years and children who are moderately or severely compromised and transition from age 11 years to 12 years, FDA allows for an alternative dosage (see above tables for guidance).
  - Children ages 6 months–4 years should receive all doses of an mRNA COVID-19 vaccine from the same manufacturer (i.e., homologous dosing).
  - People ages 5 years and older who are moderately or severely immunocompromised should receive a 3-dose initial mRNA vaccination series using vaccines from the same manufacturer.

- For special situations regarding the interchangeability of COVID-19 vaccines [click here](#).

### Booster

- Not applicable; people 6 months and older who are moderately or severely compromised may receive an additional dose of an age-appropriate updated (2023-24 Formula) vaccine, based on CDC guidelines.

---

Continued on Next Page
## COVID-19 Vaccines
*(Continued)*

### Contraindications

- History of severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine. See the package inserts or EUA Fact Sheet for a list of vaccine components.

### Precautions

- History of non-severe allergy to a component of vaccine
- History of non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type
- Moderate or severe acute illness, with or without fever
- History of Multisystem Inflammatory Syndrome in Children (MISC-C)
- History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine
- Follow [CDC Guidance on COVID-19 vaccine precautions](https://www.cdc.gov/vaccines/covid-19/advisory-committee/services/cdc-guidance.html)

### Adverse Reactions

- Syncope (fainting) may occur in association with any vaccination.
- Local reactions may include pain/tenderness, and, less commonly, swelling, and erythema at the injection site.
- Systemic reactions may include fever, irritability/crying, drowsiness/sleepiness/fatigue, malaise, headache, chills, myalgia, arthralgia.
- Localized axillary lymphadenopathy may occur on the same side as the vaccinated arm.
- Infrequently, people who have dermal fillers might experience temporary swelling at or near the site of filler injection.
- Myocarditis and pericarditis are rare adverse events, especially for males ages 12–39 years. See [COVID-19 vaccination and myocarditis and pericarditis](https://www.cdc.gov/vaccines/covid-19/advisory-committee/services/covid-19-vaccination-and-myocarditis-and-pericarditis.html) for additional information.
- Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines.
## Special Considerations

- People who recently had SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).
- Persons with a history of multisystem inflammatory syndrome, MIS-C (children), have a precaution to receipt of COVID-19 vaccine and should be referred to a provider for further evaluation.
- Development of myocarditis or pericarditis after a dose of an mRNA (Moderna, Pfizer-BioNTech) or Novavax COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine and subsequent doses should generally be avoided.
- Providers should consider observing people with the following precautions to a previously administered COVID-19 vaccine for 30 minutes if a subsequent dose of the same vaccine type is administered:
  - History of a non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type
  - History of a diagnosed non-severe allergy to a component of the COVID-19 vaccine
- Vaccination is recommended for all people aged 6 months and older, including people who are pregnant, breastfeeding, or trying to get pregnant now or who might become pregnant in the future.
- COVID-19 vaccines may be co-administered with any other indicated vaccines; no minimum interval applies to receipt of other vaccines with COVID-19 vaccines. People, particularly adolescent and young adult males, who are recommended to receive both COVID-19 and smallpox/mpox vaccines might consider waiting 4 weeks between vaccines. This is because of the observed risk of myo/pericarditis after COVID-19 and ACAM2000 vaccines, and the hypothetical risk of myo/pericarditis after JYNNEOS vaccine. However, if a patient’s risk of mpox or COVID-19 severe disease is increased, administration of mpox and COVID-19 vaccines should not be delayed.

Screen for contraindications and precautions using [DHA Form 236](https://www.health.mil/COVID19vaccineresources_HCP) before administering EACH dose, even if a vaccine was previously administered.

- VIS: [https://www.cdc.gov/vaccines/hcp/vis/vis-statements/covid-19.html](https://www.cdc.gov/vaccines/hcp/vis/vis-statements/covid-19.html)